Carfilzomib-Induced Thrombotic Microangiopathy: Focus on Pathogenesis
Open Access
- 1 June 2022
- journal article
- research article
- Published by Elmer Press, Inc. in Journal of Medical Cases
- Vol. 13 (6) , 274-280
Abstract
Carfilzomib-Induced Thrombotic Microangiopathy: Focus on PathogenesisKeywords
This publication has 36 references indexed in Scilit:
- Thrombotic microangiopathy during carfilzomib use: case series in SingaporeBlood Cancer Journal, 2016
- Proteasome inhibitor associated thrombotic microangiopathyAmerican Journal of Hematology, 2016
- Carfilzomib: A cause of drug associated thrombotic microangiopathyTransfusion and Apheresis Science, 2016
- Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre studyThe Lancet Oncology, 2016
- Thrombotic microangiopathy associated with proteasome inhibitorsClinical Kidney Journal, 2015
- Carfilzomib associated thrombotic microangiopathy initially treated with therapeutic plasma exchangeJournal of Clinical Apheresis, 2014
- Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myelomaBMC Nephrology, 2014
- Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adultsBlood, 2014
- A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myelomaBlood, 2012
- The ubiquitin‐proteasome pathway and proteasome inhibitorsMedicinal Research Reviews, 2001